TNXP · Tonix Pharmaceuticals Holding Corp.
$13.59
+0.03 (+0.22%)
At close · Aug 28
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Aug 10, 2026
Market Cap
$233.08M
Shares
17.15M
Tonix Pharmaceuticals Holding Corp. Earnings Call Transcripts
Quarterly earnings calls for Tonix Pharmaceuticals Holding Corp. (TNXP), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
Conference
Investor event
2026-08-11
Tonix Pharmaceuticals Holding Corp. (TNXP) August 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-10
Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript
Confident tone
Tonmaya launch performance
Competitor landscape (Pfizer VALOR)
TNX-4800 Lyme disease prevention
Revenue
$13.54M
▲ 577.9% YoY Diluted EPS
$-2.44
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Capital Markets Day
Investor event
2026-06-24
Tonix Pharmaceuticals Holding Corp. (TNXP) June 2026 Capital Markets Day
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-03-13
Tonix Pharmaceuticals Holding Corp. (TNXP) Q4 2025 Earnings Call
Revenue
$5.39M*
▲ 108.8% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Showing 1–4 of 4 earnings calls
Key facts
CIK
1430306
CUSIP
890260839
13F (30d)
88 filings
87 filers
Visit website
Investor relations